BeOne Medicines stock
Price history
+13.08% over the period1 year: from $368.36 (November 13, 2025) to $416.54 (November 13, 2026), +13.08%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $416.54 |
| October 30, 2026 | $370.33 |
| September 30, 2026 | $365.94 |
| August 31, 2026 | $359.58 |
| July 31, 2026 | $316.01 |
| June 30, 2026 | $284.97 |
| May 29, 2026 | $287.92 |
| April 30, 2026 | $295.27 |
| March 31, 2026 | $296.97 |
| February 27, 2026 | $316.99 |
| January 30, 2026 | $340.38 |
| December 31, 2025 | $303.81 |
| November 28, 2025 | $340.61 |
| November 13, 2025 | $368.36 |
At a glance
The company
Oncology company discovering and developing cancer treatments including commercial-stage drugs and clinical-stage candidates targeting blood cancers, solid tumors, and other malignancies
Latest results
Quarter to September 30, 2026 · EPS $3.28 (estimate $1.89)
TickerLandia's take on BeOne Medicines
- Pricier than similar companies: trailing 12-month P/E 53 vs 39 (+36%) in a group of 6.
- Strong point: Market momentum (80/100 in its group). Weak point: Earnings stability (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.93% from the 52-week high
Analysts · 27 analysts
Average target$469.23+12.65% vs. price
Buy 26 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: BeOne Medicines
Compared with similar companies: very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh63
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 33.0 67 Price/sales 7.20 38 Price/book 8.17 66 P/E (trailing 12 months) 53.4 68 Forward P/E 38.9 74 Profitabilityhigh60
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 89.4% 71 ROA 8.4% 71 ROE 18.4% 64 Operating margin 17.8% 45 Net margin 13.9% 52 Earnings stabilitylow34
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 61.5% 37 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthhigh78
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +55.69% 75 Revenue growth (year over year) +33.80% 66 Earnings growth (year over year) +212.50% 94 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −4.42 96 Interest coverage 7.68 44 Debt/equitycounts in reverse: lower means more financial strength 0.35 33 Current ratio 3.55 55 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong80
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +20.67% 92 1-year return +13.08% 50 Relative strength (6 months) +29.54% 86 Distance from 200-day average +27.07% 94 Riskaverage49
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 30.9% 54 Volatility (60 days) 32.0% 44 Beta (1 year) 0.67 49
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
BeOne Medicines is pricier than similar companies
BeOne Medicines's P/E (trailing 12 months): 53.4, +36% against the median of a group of 6 similar companies (39.3).
Compared with 6 similar companies
| Metric | BeOne Medicines | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 53.4 | High | |
| Forward P/E | 38.9 | High | |
| Operating margin | 17.8% | Middle | |
| ROE | 18.4% | High | |
| Debt/equity | 0.35 | Middle |
Grey band: the middle half of the group; tick: the median; dot: BeOne Medicines. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.71B
Latest quarter · Q2 2026
Net income
$237.01M
Latest quarter · Q2 2026
Quarterly net margin
13.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $47.58B
- P/E
- 53.4
- EPS
- $7.80
- Volume
- 345.46K
- Daily trading
- €164.64M
- Dividend yield
- 0.00%
How BeOne Medicines is changing
All resultsRevenue grew 76.8% a year on average over the last 5 years
Operating margin rose from −126.4% to 8.4%
Shares outstanding up 35.9% in 5 years
Returns
BeOne Medicines returns
$1,000 invested in BeOne Medicines 5 years ago, on November 15, 2021, would be worth $1,089 today: +8.94% in total, +1.73% per year. This is the price return only: dividends are excluded.
| Period | BeOne Medicines | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +19.33% | −3.12% | $1,193 |
| 6 months | +31.59% | +1.58% | $1,316 |
| Year to date | +37.11% | +10.46% | $1,371 |
| 1 year | +13.08% | +12.23% | $1,131 |
| 3 years | +109.47% | +71.41% | $2,095 |
| 5 years | +8.94% | +61.48% | $1,089 |
| 10 years | +1,088.42% | +249.40% | $11,884 |
Over the last 6 months it has done better than 70% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
BeOne Medicines: technical analysis
BeOne Medicines is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.8% below its all-time closing high ($424.00, November 10, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 67
- Between 30 and 70
- vs 200-session average
- +27.07%
Support and resistance
Price areas where BeOne Medicines has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$416.54
- Support$384.63−7.66%3 touches, last on October 21, 2026
- Support$372.50−10.57%3 touches, last on September 30, 2026
- Support$350.35−15.89%2 touches, last on November 3, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.67
- Volatility (60 sessions, annualised)
- 32.0%
- Largest fall in the last year
- −30.90%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
BeOne Medicines: seasonality
Average monthly price change over 11 years
Over the last 11 years, the strongest month for BeOne Medicines has been July: +14.37% on average, positive in 9 years out of 11. The weakest has been December: −4.37% on average, positive in 3 years out of 10. November, the current month, has been positive in 6 years out of 10 (+6.37% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +8.37% | +13.40% | 6 of 10 |
| February | +2.75% | +4.81% | 6 of 10 |
| March | −2.93% | −4.05% | 4 of 11 |
| April | +1.88% | −1.30% | 4 of 11 |
| May | −1.96% | −3.31% | 4 of 11 |
| June | +1.04% | −1.02% | 5 of 11 |
| July | +14.37% | +10.93% | 9 of 11 |
| August | +4.36% | +2.13% | 7 of 11 |
| September | +6.48% | +7.31% | 7 of 11 |
| October | −0.30% | +1.20% | 6 of 11 |
| November | +6.37% | +3.23% | 6 of 10 |
| December | −4.37% | −6.37% | 3 of 10 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
BeOne Medicines and its competitors
BRUKINSA and TEVIMBRA are the medicines most closely associated with BeOne Medicines AG, which was known as BeiGene until its renaming in May 2025. BRUKINSA, a BTK inhibitor, is used against several blood cancers, while TEVIMBRA is an anti-PD-1 antibody that treats solid tumors and blood cancers. The pipeline includes candidates such as sonrotoclax, a Bcl-2 inhibitor, and zanidatamab, a HER2-targeted bispecific antibody. Partners include Amgen, BMS, Novartis and Luye Pharmaceutical, and the company holds an agreement with the U.S. government on access to cancer medicines.
- Headquarters
- Basel, Switzerland
- Employees
- 12,000
- Founded
- 2010
- Chief executive
- John Oyler
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| BeOne MedicinesONC | $47.58B | 17.8% | 53.4 | +31.59% |
| Royalty PharmaRPRX | $39.85B | 64.4% | 45.3 | +30.16% |
| argenxARGX | $60.37B | 31.9% | 33.3 | +19.60% |
| Revolution MedicinesRVMD | $37.27B | -853.0% | — | +14.91% |
| Roivant SciencesROIV | $28.64B | -3,226.3% | — | +35.28% |
| InsmedINSM | $26.58B | -41.7% | — | +2.69% |
Same industry or related industries, similar size. Compare BeOne Medicines with its competitors · Full profile
